Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

événements et presentations

 
 

Corporate presentation

Financial calendar

  • March 24, 2026
    2025 Full-year Results
  • April 29, 2026
    First Half 2026 Financial Results
  • November 9, 2026
    Third Quarter 2026 Financial Results
 

Webcasts

  • June 29, 2026
    Transgene expands myvac®into NSCLC with TG4070
  • March 24, 2026
    2025 Full-year results and business update
  • November 14, 2025
    TG4050 at 2025 SITC: New Ph.I immunological data
  • June 6, 2025
    Listen to Prof. Ottensmeier explain the TG4050 Phase 1 data
 

Investor events

     
    Get to know us

    About us

    myvac

    Pipeline

    Investors

    Partnering

    Company

    Career

    ESG

    Suppliers

    Contacts

    Legal documents

    Legal notices

    Privacy Policy

    Ethics and compliance

    Cookie policy

    • About us
      • About us
      • Executive commitee
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • ESG
    • myvac
      • myvac – individualized therapeutic vaccines
    • Pipeline
      • Pipeline
      • TG4050
      • TG4070
      • BT-001
      • TG6050
      • Publications and Presentations
      • Clinical trials FAQ
    • Investors
      • Investor Presentation & Contacts
      • Press releases & events
      • Financial Information
      • Stock Information
      • Annual General Meeting
    • Career
    • English
    • French
    Menu